<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239950</url>
  </required_header>
  <id_info>
    <org_study_id>MND2112H33</org_study_id>
    <secondary_id>20191474</secondary_id>
    <nct_id>NCT04239950</nct_id>
  </id_info>
  <brief_title>Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in
      Chinese patients with severe hypertriglyceridemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events after the start of study drug administration</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum total cholesterol level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum low-density lipoprotein cholesterol (LDL-C) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum high-density lipoprotein cholesterol (HDL-C) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction after the start of study drug administration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl Icosapentate 1.8g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethyl Icosapentate 3.6g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyl Icosapentate</intervention_name>
    <description>Ethyl Icosapentate</description>
    <arm_group_label>Ethyl Icosapentate 1.8g</arm_group_label>
    <arm_group_label>Ethyl Icosapentate 3.6g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients whose serum Triglyceride (TG) level (fasting) from week -6 to week -4 is 500
             mg/dL or higher and less than 2,000 mg/dL

          2. Patients who receive instructions for lifestyle improvement and are able to comply
             with all instructions throughout the study participation period

          3. Patients who are 18 to &lt; 75 years of age, regardless of sex, at the time of informed
             consent

          4. Patients who have provided written consent to participate in this clinical trial

          5. Patients whose serum TG level (fasting) is 500 mg/dL or higher and less than 2,000
             mg/dL at Visit 2 (Week -2)

          6. Patients whose serum TG level (fasting) is 500 mg/dL or higher and less than 2,000
             mg/dL at Visit 3 (Week -1)

          7. Patients in whom the difference between Visit 2 (Week -2) and Visit 3 (Week -1) in
             serum TG level (fasting) is not more than 50% of the higher value

          8. Outpatients

        Exclusion Criteria:

          1. Patients whose HbA1c from week -6 to week -4 is 8.0% or higher

          2. Patients whose Alanine Aminotransferase (ALT) or Aspartate aminotransferase (AST) from
             week -6 to week -4 is more than 3 times the upper limit of normal

          3. Patients with, or with a history of, angina pectoris or myocardial infarction

          4. Patients with a history of percutaneous transluminal coronary angioplasty or coronary
             artery bypass grafting

          5. Patients with familial lipoprotein lipase (LPL) deficiency, familial apolipoprotein
             C-II (apo C-II) deficiency, or familial type III, IV hyperlipidemia

          6. Patients with hypothyroidism, Cushing's syndrome, acromegaly, nephrotic syndrome,
             chronic renal failure, systemic lupus erythematosus, myeloma, or nonalcoholic
             steatohepatitis (NASH)

          7. Patients with hyperlipidemia induced by drugs (e.g., corticosteroids, beta-blockers,
             contraceptives, interferons, retinoids, and diuretics)

          8. Patients with, or with a history of, alcohol dependence or abuse or patients whose
             hyperlipidemia is presumed to be primarily caused by alcohol

          9. Patients with aortic aneurysm or who have undergone aortic aneurysmectomy within the
             last 6 months

         10. Patients with uncontrollable hypertension (patients with a systolic blood pressure of
             ≥180 mmHg or a diastolic blood pressure of ≥110 mmHg in a sitting position at Visit 1
             (Week -4))

         11. Patients with, or with a history of, pancreatitis or patients suspected as
             pancreatitis by examination, etc

         12. Patients with a diagnosis of complication of pancreas or bile duct-related neoplastic
             disease

         13. Patients with type 1 diabetes mellitus or type 2 diabetes mellitus requiring insulin
             therapy

         14. Patients with any of the following hemorrhagic findings within the last 6 months:

               -  Patients with, or with a history of, clinically significant hemorrhagic disease
                  (e.g., cerebral hemorrhage, hemophilia, capillary fragility, gastrointestinal
                  [GI] ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage)

               -  Patients with clinically significant bleeding tendency (e.g., menorrhagia,
                  frequent epistaxis)

               -  Patients with, or with a history of, severe trauma

               -  Patients with a history of surgery requiring blood transfusion

         15. Patients who have taken any EPA product

         16. Patients who have received a PCSK9 (human proprotein convertase subtilisin/kexin type
             9) inhibitor to treat hyperlipidemia

         17. Patients who have taken antihyperlipidemic drugs within the last 4 weeks

         18. Pregnant, possibly pregnant, or lactating women

         19. Patients with a history of hypersensitivity to polyunsaturated fatty acids or gelatin

         20. Patients with, or with a history of, malignant tumor

         21. Patients with any serious disease, including hepatic, renal, hematologic, respiratory,
             GI, cardiovascular, psychological, neurologic, metabolic, and electrolyte disorders,
             or hypersensitivity

         22. Patients who have received any other investigational drug within the last 3 months

         23. Patients who are judged by the principal (or sub-) investigator to be ineligible as a
             study subject for any other reason

         24. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of
             ≥110 mmHg at Visit 2 (Week -2))

         25. Patients who have changed the dosage of antidiabetic drug (except insulin) or who have
             switched from one drug to another since Visit 1 (Week -4)

         26. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of
             ≥110 mmHg at Visit 3 (Week -1)

         27. Patients with an HbA1c level of ≥8.0% at Visit 2 (Week -2)

         28. Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 2
             (Week -2)

         29. Patients with a systolic blood pressure of ≥180 mmHg or a diastolic blood pressure of
             ≥110 mmHg at Visit 4 (Week 0)

         30. Patients with an HbA1c level of ≥8.0% at Visit 3 (Week -1)

         31. Patients whose ALT or AST is more than 3 times the upper limit of normal at Visit 3
             (Week -1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoko Omori</last_name>
    <role>Study Director</role>
    <affiliation>Mochida Pharmaceutical Company, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mochida Clinical Research Department</last_name>
    <phone>+81-3-3225-6331</phone>
    <email>clinical.trials.contact@mochida.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mochida Public Relations Office</last_name>
    <email>webmaster@mochida.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mochida Investigational sites</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

